Second-generation antipsychotics and tardive syndromes in affective illness: A public health problem with neuropsychiatric consequences

F.M. Jacobsen

American Journal of Public Health, 2015, vol. 105, issue 2, e10-e16

Abstract: Food and Drug Administration-approved information and public advertisements belieneurode generative risks for second-generation antipsychotics in affective illness. Package inserts label tardive syndromes "potentially reversible" while uniformly omitting patient counseling for long-termneurodegenerative side effects. I found that only 2 of 78 outpatients exposed to second-generation antipsychotics reported awareness of tardive syndromes. Updated literature challenges safety advantages of atypical versus typical antipsychotics. Physician and patient information regarding tardive syndromes from second-generation antipsychotics approved for affective illnessis in adequate.

Keywords: neuroleptic agent, central nervous system; drug effects; drug labeling; food and drug administration; human; Mood Disorders; Movement Disorders; United States, Antipsychotic Agents; Central Nervous System; Drug Labeling; Humans; Mood Disorders; Movement Disorders; United States; United States Food and Drug Administration (search for similar items in EconPapers)
Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.2105/AJPH.2014.302439

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:aph:ajpbhl:10.2105/ajph.2014.302439_9

DOI: 10.2105/AJPH.2014.302439

Access Statistics for this article

American Journal of Public Health is currently edited by Alfredo Morabia

More articles in American Journal of Public Health from American Public Health Association
Bibliographic data for series maintained by Christopher F Baum ().